YTHDF1 increases RPN2 expression through m6A modification, which subsequently activates the PI3K/AKT/mTOR signaling pathway, thereby endowing cells with greater survival capabilities and increasing cisplatin resistance.24 Under conditions of low YTHDC1 expression, BC cells exhibit even higher resistance to cisplatin. Here, MTOR is linked to breast cancer.